80 PDRN


supplies nucleotides during repair demand.1-3 This dual rationale is particularly attractive in cosmetology, where stressed skin must often balance inflammation control with rebuilding. The recombinant PDRN platform we


review here is produced through biosynthetic manufacturing rather than direct animal extraction. The DNA sequence source is salmon- derived, but the material itself is generated by fermentation, enabling tighter process control and removing direct reliance on fish tissue extraction. In finished form it is supplied as sodium DNA, a white water-soluble powder suitable for lotions, creams, masks and eye-area formats, with a working pH range of approximately 5.0-9.0. One of the more significant formulation


advantages of this recombinant approach is molecular consistency. Our internal characterisation indicates that the fragment population is distributed within a well-controlled size profile, helping to improve standardisation relative to less controlled extractive materials. In principle, such control should influence both batch reproducibility and skin-delivery behaviour. It also creates a path toward function-oriented sequence design rather than reliance on whatever fragment spectrum is recovered during extraction. Our studies indicate that the ingredient exerts


its effects through two main pathways. The first is adenosine A2A receptor-associated signalling, consistent with the broader PDRN literature, where downstream effects have included reduced pro-inflammatory cytokine expression and improved regenerative signalling.1-3 The second is support for salvage synthesis by


supplying nucleic-acid building blocks relevant to DNA repair processes. For skin exposed to UV, pollution, irritation or barrier compromise, this is a compelling framework because repair efficiency depends not only on calming inflammation but also on providing the molecular resources required for recovery. Our in vitro data support this positioning.


In cytotoxicity work on L929 and HFF-1 cells, recombinant PDRN showed no cytotoxicity up to 500 µg/mL, suggesting a broad safety window for cosmetic development. Across screening experiments, 100-200 µg/mL emerged as a practical concentration range balancing safety with pro-proliferative and anti-inflammatory


con ■ 10 ■ 50 ■ 100 ■ 200 ■ 500 ■


400 300 200 100 0


24 48 Figure 1: Effect of recombinant PDRN on L929 cell proliferation con ■ 10 ■ 50 ■ 100 ■ 200 ■ 500 ■


400 300 200 100 0


24 48 Figure 2: Effect of recombinant PDRN on HFF-1 cell proliferation


performance. In a scratch-wound model, treatment with 100 µg/mL recombinant PDRN increased the relative healing rate to 131% versus the control at 41 hours, indicating enhanced cell migration associated with wound closure behaviour. In our comparative fibroblast testing at 100


µg/mL, both recombinant PDRN and a salmon- extracted comparator promoted type I and type III collagen synthesis, with recombinant PDRN demonstrating superior performance overall. This is meaningful because collagen I is closely tied to dermal tensile strength and wrinkle-related structural support. The ingredient also showed significant anti-inflammatory activity in the


Control ■ RJMPDRN REC ■ *


0.2


supplied test system. An especially practical finding is the synergy


observed with sodium hyaluronate. When recombinant PDRN and hyaluronate were combined at 50 µg/mL each, cell migration in the scratch model outperformed PDRN alone, supporting the idea that nucleic-acid repair support and hydration/matrix lubrication can be combined for more robust visible-care effects. This positions recombinant PDRN not only as a standalone repair active but also as a strong co-active for moisturising and barrier-focused systems. Beyond the in vitro profile, our 28-day in vivo


study further supports the cosmetic relevance of recombinant PDRN. In a panel of 31 female subjects with sensitive skin aged 25-50 years using a 0.1% aqueous solution twice daily, the material delivered highly significant improvements at both 14 and 28 days across multiple instrumental endpoints. After 28 days, transepidermal water loss


0.1 0.0 17H Figure 3: Cell scratch assay PERSONAL CARE MAGAZINE September 2026 24H 41H


decreased by 17.37%, elasticity parameter R2 increased by 30.11%, firmness parameter F4 decreased by 19.83%, erythema index decreased by 12.40%, wrinkle area decreased by 7.44%, wrinkle length decreased by 11.44% and wrinkle count decreased by 46.67% versus baseline. No adverse reactions were reported during the test, and the study conclusion supported moisturizing, repairing, soothing, firming and anti-wrinkle efficacy under the test conditions.


www.personalcaremagazine.com 72 72


Cell Migration Rate (%)


Cell Survival Rate (%)


Cell Survival Rate (%)


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92